IMF co-founders Susie and Brian Durie receive honorary doctorate from Vrije Univesiteit Brussel

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

International Myeloma Foundation co-founder and president, Susie Durie, and Chairman Brian Durie were awarded a joint honorary doctorate for scientific excellence from the Vrije Universiteit Brussel at a ceremony in Brussels.

Honorary doctorates were also bestowed upon Swedish statistician Hans Rosling (given posthumously), French mathematics historian Karine Chemla, Belgian pioneering mathematician Freddy Van Oystaeyen, American mathematician and champion of better STEM education Padmanabhan Seshaiyer, Dutch physicist and science communicator Robbert Dijkgraaf, and political cartoonist Gerard Alsteens.

The university praised what its leadership called Durie’s “extraordinary” merit: “He is at the foundation of the development of new diagnostic and therapeutic possibilities, which have led to a significant increase in life expectancy following the diagnosis of multiple myeloma.” Together with Susie Durie, they founded the IMF “to inform patients and to involve them in the knowledge about their illness, but also to encourage doctors worldwide to work together to develop best practice guidelines.”

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login